US Secures World Stock of Key COVID-19 Drug Remdesivir
The U.S. has bought up virtually all the stocks of remdesivir, perhaps the most closely watched experimental drug to treat COVID-19. The Guardian reports: Remdesivir, the first drug approved by licensing authorities in the U.S. to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead's production for July and 90% of August and September. "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19," said the U.S. health and human services secretary, Alex Azar. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people." The drug, which was trialled in the Ebola epidemic but failed to work as expected, is under patent to Gilead, which means no other company in wealthy countries can make it. The cost is around $3,200 per treatment of six doses, according to the US government statement. The deal was announced as it became clear that the pandemic in the U.S. is spiralling out of control. Anthony Fauci, the country's leading public health expert and director of the National Institute of Allergy and Infectious Diseases, told the Senate the U.S. was sliding backwards.
from Slashdot https://ift.tt/2VBXm7p
Read more of this story at Slashdot.
from Slashdot https://ift.tt/2VBXm7p
0 Response to "US Secures World Stock of Key COVID-19 Drug Remdesivir"
Post a Comment